Related references
Note: Only part of the references are listed.Selective N-Terminal BET Bromodomain Inhibitors by Targeting Non-Conserved Residues and Structured Water Displacement**
Huarui Cui et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Current development of CBP/p300 inhibitors in the last decade
Zhang-Xu He et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of a hidden transient state in all bromodomain families
Lluis Raich et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development
Pan Tang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection
Richard J. Mills et al.
CELL (2021)
The BET family in immunity and disease
Nian Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
More Insights into the Association between RVX-208 and Pulmonary Arterial Hypertension
Dong Ning et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2020)
In silico design and molecular basis for the selectivity of Olinone toward the first over the second bromodomain of BRD4
Yoel Rodriguez et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2020)
Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
George M. Burslem et al.
CELL (2020)
Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer
Emily J. Faivre et al.
NATURE (2020)
Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites
Michael D. Olp et al.
ACS CHEMICAL BIOLOGY (2020)
Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery
Dailin Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes A Randomized Clinical Trial
Kausik K. Ray et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation
Omer Gilan et al.
SCIENCE (2020)
Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain
George S. Sheppard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer
P. Jake Slavish et al.
CANCER RESEARCH (2020)
Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins
Alex Preston et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor
Jonathan T. Seal et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins
Robert J. Watson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype
Christopher R. Wellaway et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Recent Advances in the Development of CBP/p300 Bromodomain Inhibitors
Ying Xiong et al.
CURRENT MEDICINAL CHEMISTRY (2020)
Proteolysis-targeting chimaeras mediated the degradation of bromodomain and extra-terminal domain proteins
Yifei Yang et al.
FUTURE MEDICINAL CHEMISTRY (2020)
GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family
Alex Preston et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader
Frances Potjewyd et al.
CELL CHEMICAL BIOLOGY (2020)
Insight into selective mechanism of class of I-BRD9 inhibitors toward BRD9 based on molecular dynamics simulations
Jing Su et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2019)
Computational study on the selective inhibition mechanism of MS402 to the first and second bromodomains of BRD4
Qianqian Wang et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2019)
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
Sophie Postel-Vinay et al.
EUROPEAN JOURNAL OF CANCER (2019)
Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension
Diederik E. Van der Feen et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
Lu Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Targeted protein degradation: elements of PROTAC design
Stacey-Lynn Paiva et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2019)
Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV
Qingli Niu et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Bromodomains: a new target class for drug development
Andrea G. Cochran et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism
Laura M. Tsujikawa et al.
CLINICAL EPIGENETICS (2019)
Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins
Deheng Chen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Bromodomain biology and drug discovery
Nilesh Zaware et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2019)
MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53
John Hines et al.
CANCER RESEARCH (2019)
Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel-Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7
Vittoria Zoppi et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of Benzo[cd]indol-2(1H)-ones and Pyrrolo[4,3,2-de]quinolin-2(1H)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis
Fei Jiang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
A Click Chemistry Platform for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation
Ryan P. Wurz et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
Calla M. Olson et al.
NATURE CHEMICAL BIOLOGY (2018)
Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors
William R. Shadrick et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer
Qiuping Xiang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation
Zhiqing Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Structure-based discovery of selective BRPF1 bromodomain inhibitors
Jian Zhu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors
Jeremy Lewin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain
Robert P. Law et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression
Chong Qin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Apabetalone Mediated Epigenetic Modulation is Associated with Favorable Kidney Function and Alkaline Phosphatase Profile in Patients with Chronic Kidney Disease
Ewelina Kulikowski et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2018)
Plasticity in binding confers selectivity in ligand-induced protein degradation
Radoslaw P. Nowak et al.
NATURE CHEMICAL BIOLOGY (2018)
Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
Lara N. Gechijian et al.
NATURE CHEMICAL BIOLOGY (2018)
Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach
Zuni I. Bassi et al.
ACS CHEMICAL BIOLOGY (2018)
Classical molecular dynamics and metadynamics simulations decipher the mechanism of CBP30 selectively inhibiting CBP/p300 bromodomains
Qianqian Wang et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2018)
Targeting Brd4 for cancer therapy: inhibitors and degraders
Yingchao Duan et al.
MEDCHEMCOMM (2018)
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Quinlan L. Sievers et al.
SCIENCE (2018)
Large-scale analysis of water stability in bromodomain binding pockets with grand canonical Monte Carlo
Matteo Aldeghi et al.
COMMUNICATIONS CHEMISTRY (2018)
The polar warhead of a TRIM24 bromodomain inhibitor rearranges a water-mediated interaction network
Jiuyang Liu et al.
FEBS JOURNAL (2017)
In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)
Nobumichi Ohoka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Rapid and Reliable Binding Affinity Prediction of Bromodomain Inhibitors: A Computational Study
Shunzhou Wan et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2017)
GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)
F. Anthony Romero et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Predictions of Ligand Selectivity from Absolute Binding Free Energy Calculations
Matteo Aldeghi et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)
Distinct Roles of Brd2 and Brd4 in Potentiating the Transcriptional Program for Th17 Cell Differentiation
Ka Lung Cheung et al.
MOLECULAR CELL (2017)
RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease
Ravi Jahagirdar et al.
MOLECULAR PHARMACOLOGY (2017)
Structural basis of PROTAC cooperative recognition for selective protein degradation
Morgan S. Gadd et al.
NATURE CHEMICAL BIOLOGY (2017)
Marked for death: targeting epigenetic changes in cancer
Sophia Xiao Pfister et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Functions of bromodomain-containing proteins and their roles in homeostasis and cancer
Takao Fujisawa et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice
Kalung Cheung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Selective BET bromodomain inhibition as an antifungal therapeutic strategy
Flore Mietton et al.
NATURE COMMUNICATIONS (2017)
Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations
Qianqian Wang et al.
SCIENTIFIC REPORTS (2017)
Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer
Lingyan Jin et al.
CANCER RESEARCH (2017)
Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action
Amaury E. Fernandez-Montalvan et al.
ACS CHEMICAL BIOLOGY (2017)
Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation
Julia C. Meier et al.
ACS CHEMICAL BIOLOGY (2017)
Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation
Nilesh Zaware et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2017)
Beyond the BET Family: Targeting CBP/p300 with 4-Acyl Pyrroles
Martin Huegle et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
Targeted Protein Degradation: from Chemical Biology to Drug Discovery
Philipp M. Cromm et al.
CELL CHEMICAL BIOLOGY (2017)
BET inhibitors: a novel epigenetic approach
D. B. Doroshow et al.
ANNALS OF ONCOLOGY (2017)
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Longchuan Bai et al.
CANCER RESEARCH (2017)
Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands
David Remillard et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2017)
The Bromodomain: A New Target in Emerging Epigenetic Medicine
Steven G. Smith et al.
ACS CHEMICAL BIOLOGY (2016)
Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B
Peiling Chen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition
Natalie H. Theodoulou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor
Wylie S. Palmer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease
Dean Gilham et al.
ATHEROSCLEROSIS (2016)
RVX-297-a novel BD2 selective inhibitor of BET bromodomains
Olesya A. Kharenko et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
Bromodomains: Structure, function and pharmacology of inhibition
Elena Ferri et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112
Beth E. Zucconi et al.
BIOCHEMISTRY (2016)
Progress in the Development of non-BET Bromodomain Chemical Probes
Natalie H. Theodoulou et al.
CHEMMEDCHEM (2016)
Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor
Laetitia J. Martin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Development of Selective CBP/P300 Benzoxazepine Bromodomain Inhibitors
Tobias A. Popp et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Garrett W. Rhyasen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Epigenetic drug discovery: breaking through the immune barrier
David F. Tough et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Kanak Raina et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain
Paul Bamborough et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637)
Alexander M. Taylor et al.
ACS MEDICINAL CHEMISTRY LETTERS (2016)
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Honorine Lebraud et al.
ACS CENTRAL SCIENCE (2016)
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
Sarah Picaud et al.
CANCER RESEARCH (2015)
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNFMutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
Bhavatarini Vangamudi et al.
CANCER RESEARCH (2015)
Discovery of Chemical Inhibitors of Human Bromodomains
Guangtao Zhang et al.
CHEMICAL REVIEWS (2015)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
An evaluation of RVX-208 for the treatment of atherosclerosis
Dragana Nikolic et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors
Paul Bamborough et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B
Ludovic Drouin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses
Ariane Hammitzsch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains
Duncan A. Hay et al.
MEDCHEMCOMM (2015)
Targeting BET bromodomains for cancer treatment
Marie Jung et al.
EPIGENOMICS (2015)
Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
Stuart W. J. Ember et al.
ACS CHEMICAL BIOLOGY (2014)
Selective Chemical Modulation of Gene Transcription Favors Oligodendrocyte Lineage Progression
Mar Gacias et al.
CHEMISTRY & BIOLOGY (2014)
Discovery and Optimization of Small-Molecule Ligands for the CBP/p300 Bromodomains
Duncan A. Hay et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Junwei Shi et al.
MOLECULAR CELL (2014)
Targeting bromodomains: epigenetic readers of lysine acetylation
Panagis Filippakopoulos et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Gang Lu et al.
SCIENCE (2014)
1,3-Dimethyl Benzimidazolones Are Potent, Selective Inhibitors of the BRPF1 Bromodomain
Emmanuel H. Demont et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Structure-Guided Design of Potent Diazobenzene Inhibitors for the BET Bromodomains
Guangtao Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Acetylation of RNA Polymerase II Regulates Growth-Factor-Induced Gene Transcription in Mammalian Cells
Sebastian Schroeder et al.
MOLECULAR CELL (2013)
RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain
Sarah Picaud et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Panagis Filippakopoulos et al.
CELL (2012)
Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites
Lewis R. Vidler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
BET domain co-regulators in obesity, inflammation and cancer
Anna C. Belkina et al.
NATURE REVIEWS CANCER (2012)
Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genes
Janine M. Lamonica et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription
MK Jang et al.
MOLECULAR CELL (2005)
Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein brd4
ZY Yang et al.
MOLECULAR CELL (2005)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
